

# Dudley J Pennell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250159/publications.pdf>

Version: 2024-02-01

249  
papers

27,589  
citations

12330

69  
h-index

5539

163  
g-index

271  
all docs

271  
docs citations

271  
times ranked

16649  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence to support magnetic resonance conditional labelling of all pacemaker and defibrillator leads in patients with cardiac implantable electronic devices. <i>European Heart Journal</i> , 2022, 43, 2469-2478.	2.2	22
2	Normal values of MAPSE and TAPSE in the paediatric population established by cardiovascular magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 407-409.	1.5	1
3	Predicting Survival in Repaired Tetralogy of Fallot. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 257-268.	5.3	37
4	Cardiovascular Magnetic Resonance for Patients With COVID-19. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 685-699.	5.3	79
5	Imaging Findings of COVID-19-Related Cardiovascular Complications. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 79-93.	1.7	4
6	Exposure to Elevated Nitrogen Dioxide Concentrations and Cardiac Remodeling in Patients With Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2022, 28, 924-934.	1.7	6
7	Development of a cardiovascular magnetic resonance-compatible large animal isolated heart model for direct comparison of beating and arrested hearts. <i>NMR in Biomedicine</i> , 2022, , e4692.	2.8	2
8	Spontaneous Coronary Artery Dissection: Insights From Cardiac Magnetic Resonance and Extracoronary Arterial Screening. <i>Circulation</i> , 2022, 145, 555-557.	1.6	3
9	Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. <i>ESC Heart Failure</i> , 2022, 9, 1616-1624.	3.1	3
10	Accelerating Cardiac Diffusion Tensor Imaging With a U-Net Based Model: Toward Single Breath-Hold. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1691-1704.	3.4	7
11	Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 29.	3.3	13
12	Performance of Cardiac MRI in Pediatric and Adult Patients with Fontan Circulation. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, .	2.5	4
13	Late-Gadolinium Enhancement Interface Area and Electrophysiological Simulations Predict Arrhythmic Events in Patients With Nonischemic Dilated Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 238-249.	3.2	13
14	Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from <scp>TREDâ€CHF</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 293-301.	7.1	19
15	CMR unveiling the cause of post CoVid-19 infection chest pain. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2025-2026.	1.5	2
16	Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a). <i>Antioxidants</i> , 2021, 10, 132.	5.1	4
17	Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 26.	3.3	11
18	Left ventricular noncompaction in pediatric population: could cardiovascular magnetic resonance derived fractal analysis aid diagnosis?. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 90.	3.3	2

#	ARTICLE	IF	CITATIONS
19	Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy. JACC: Heart Failure, 2021, 9, 509-517.	4.1	7
20	Clinical Significance of Partial Anomalous Pulmonary Venous Connections (Isolated and Atrial Septal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Imaging, 2021, 14, e012371.	2.6	9
21	Invasive and Non-Invasive Imaging for Ischaemia with No Obstructive Coronary Artery Disease. Cardiovascular Imaging Asia, 2021, 5, 83.	0.1	2
22	Cardiovascular magnetic resonance normal values in children for biventricular wall thickness and mass. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 1.	3.3	28
23	A novel cardiovascular magnetic resonance risk score for predicting mortality following surgical aortic valve replacement. Scientific Reports, 2021, 11, 20183.	3.3	6
24	OUP accepted manuscript. European Heart Journal, 2021, , .	2.2	2
25	Myocardial deformation assessed by CMR in children after multisystem inflammatory syndrome (MIS-C). International Journal of Cardiology, 2021, 346, 105-106.	1.7	5
26	Cardiac Diffusion: Technique and Practical Applications. Journal of Magnetic Resonance Imaging, 2020, 52, 348-368.	3.4	27
27	Diffusion Tensor Cardiovascular Magnetic Resonance Imaging. JACC: Cardiovascular Imaging, 2020, 13, 1235-1255.	5.3	45
28	The year in cardiology: imaging. European Heart Journal, 2020, 41, 739-747.	2.2	7
29	Diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy: a comparison of motion-compensated spin echo and stimulated echo techniques. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 331-342.	2.0	2
30	Predictors and Mechanisms of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 136, 140-148.	1.6	8
31	Three-Dimensional Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Predicts Inducibility of Ventricular Tachycardia in Adults With Repaired Tetralogy of Fallot. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008321.	4.8	25
32	SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 76.	3.3	169
33	A model based on clinical parameters to identify myocardial late gadolinium enhancement by magnetic resonance in patients with aortic stenosis: An observational study. JRSM Cardiovascular Disease, 2020, 9, 204800402092240.	0.7	1
34	Automating in vivo cardiac diffusion tensor postprocessing with deep learning-based segmentation. Magnetic Resonance in Medicine, 2020, 84, 2801-2814.	3.0	15
35	Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 19.	3.3	467
36	Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. Annals of Hematology, 2020, 99, 2009-2017.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. Journal of Clinical Lipidology, 2019, 13, 788-796.	1.5	7
38	Diffusion tensor cardiovascular magnetic resonance. Postgraduate Medical Journal, 2019, 95, 433-438.	1.8	7
39	Assessment of Cardiac Function. , 2019, , 192-207.e4.		0
40	Cardiovascular Magnetic Resonance to Guide and Monitor the Myocardial Response to Treatment. Circulation: Cardiovascular Imaging, 2019, 12, e010045.	2.6	1
41	Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. JACC: Cardiovascular Imaging, 2019, 12, 1645-1655.	5.3	187
42	Prediction and prevention of heart failure in high-risk elderly patients. European Heart Journal, 2019, 40, 539-541.	2.2	2
43	Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet, The, 2019, 393, 61-73.	13.7	379
44	High resolution in vivo DT-CMR using an interleaved variable density spiral STEAM sequence. Magnetic Resonance in Medicine, 2019, 81, 1580-1594.	3.0	6
45	Microvascular Dysfunction in Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 1699-1708.	5.3	49
46	The evolving role of cardiac magnetic resonance in primary mitral regurgitation: ready for prime time?. European Heart Journal Cardiovascular Imaging, 2019, 20, 123-130.	1.2	17
47	Cardiovascular Magnetic Resonance Assessment of Right Ventricular Anatomy and Function. , 2019, , 454-468.e4.		1
48	Coronary Artery and Sinus Velocity and Flow. , 2019, , 309-324.e3.		0
49	Cardiac Iron Loading and Myocardial T2*. , 2019, , 400-409.e4.		0
50	Deranged Myocyte Microstructure in Situs Inversus Totalis Demonstrated by Diffusion Tensor Cardiac Magnetic Resonance. JACC: Cardiovascular Imaging, 2018, 11, 1360-1362.	5.3	15
51	What is CMR doing for patients today?. European Heart Journal, 2018, 39, 266-270.	2.2	3
52	Diffusion tensor cardiovascular magnetic resonance with a spiral trajectory: An in vivo comparison of echo planar and spiral stimulated echo sequences. Magnetic Resonance in Medicine, 2018, 80, 648-654.	3.0	11
53	Response by Halliday et al to Letter Regarding Article, "Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients with Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction". Circulation, 2018, 137, 101-102.	1.6	0
54	Diffusion Tensor Cardiovascular Magnetic Resonance of Microstructural Recovery in Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2018, 11, 1548-1550.	5.3	18

#	ARTICLE	IF	CITATIONS
55	Identification of myocardial diffuse fibrosis by 11 heartbeat MOLLI T1 mapping: averaging to improve precision and correlation with collagen volume fraction. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2018, 31, 101-113.	2.0	11
56	Major adverse events and atrial tachycardia in Ebstein's anomaly predicted by cardiovascular magnetic resonance. <i>Heart</i> , 2018, 104, 37-44.	2.9	26
57	Evaluation of the impact of strain correction on the orientation of cardiac diffusion tensors with in vivo and ex vivo porcine hearts. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 2205-2215.	3.0	18
58	Perfusion abnormalities in hypertrophic cardiomyopathy: mechanisms and prognostic importance. , 2018, , .		1
59	MRI-conditionality has no impact on pacemaker and defibrillator lead parameter changes with MRI at 1.5 t. , 2018, , .		0
60	Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis. <i>Scientific Reports</i> , 2018, 8, 14550.	3.3	6
61	Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007722.	2.6	42
62	An in-vivo comparison of stimulated-echo and motion compensated spin-echo sequences for 3T diffusion tensor cardiovascular magnetic resonance at multiple cardiac phases. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 1.	3.3	78
63	Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot. <i>International Journal of Cardiology</i> , 2018, 272, 64-69.	1.7	14
64	Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018, 20, 1392-1400.	7.1	92
65	Stochastic Deep Compressive Sensing for the Reconstruction of Diffusion Tensor Cardiac MRI. <i>Lecture Notes in Computer Science</i> , 2018, , 295-303.	1.3	22
66	Assessment of the microstructure in recovered dilated cardiomyopathy with diffusion tensor cardiovascular magnetic resonance. , 2018, , .		0
67	Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. <i>Hematology</i> , 2017, 22, 1-7.	1.5	21
68	Anomalous drainage of isolated superior caval vein to the left atrium: the oldest reported unrepaired case. <i>Cardiology in the Young</i> , 2017, 27, 1008-1010.	0.8	2
69	Assessment of Myocardial Microstructural Dynamics by In-Vivo Diffusion Tensor Cardiac Magnetic Resonance. <i>Journal of the American College of Cardiology</i> , 2017, 69, 661-676.	2.8	171
70	Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. <i>European Heart Journal</i> , 2017, 38, 1561-1569.	2.2	71
71	Sudden cardiac death risk stratification in patients with mild dilated cardiomyopathy. <i>Heart</i> , 2017, 103, A2.1-A2.	2.9	0
72	CARDIOVASCULAR MAGNETIC RESONANCE IN SURVIVORS OF SUDDEN CARDIAC ARREST: 14 YEAR EXPERIENCE FROM A TERTIARY REFERRAL CENTRE IN THE UNITED KINGDOM. <i>Journal of the American College of Cardiology</i> , 2017, 69, 491.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2017, 135, 2106-2115.	1.6	265
74	Effect of Pregnancy on Ventricular and Aortic Dimensions in Repaired Tetralogy of Fallot. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	18
75	Immediate and Midterm Cardiac Remodeling After Surgical Pulmonary Valve Replacement in Adults With Repaired Tetralogy of Fallot. <i>Circulation</i> , 2017, 136, 1703-1713.	1.6	84
76	Phenotype and Clinical Outcomes of Titin-Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2264-2274.	2.8	86
77	Relationship between plasma concentrations of b-type natriuretic peptide and exercise capacity in hypertrophic cardiomyopathy. <i>Heart</i> , 2017, 103, A96-A97.	2.9	0
78	Incremental diagnostic value of cardiovascular magnetic resonance in young adult survivors of sudden cardiac arrest. <i>Heart</i> , 2017, 103, A39-A39.	2.9	1
79	Oxidised ldl levels correlate with lipoprotein(a) levels and are reduced by lipoprotein apheresis in a randomised study on patients with refractory angina and raised lipoprotein(a). <i>Heart</i> , 2017, 103, A69.1-A69.	2.9	0
80	Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. <i>PLoS ONE</i> , 2017, 12, e0181077.	2.5	11
81	Burden of Cardiac Siderosis in a Thalassemia-Major Endemic Population: A Preliminary Report From Pakistan. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 378-383.	0.6	7
82	Cardiac complications in thalassemia major. <i>Annals of the New York Academy of Sciences</i> , 2016, 1368, 56-64.	3.8	29
83	The effects of noise in cardiac diffusion tensor imaging and the benefits of averaging complex data. <i>NMR in Biomedicine</i> , 2016, 29, 588-599.	2.8	32
84	Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2016, 18, 703-712.	7.1	62
85	Fast Fully Automatic Segmentation of the Severely Abnormal Human Right Ventricle from Cardiovascular Magnetic Resonance Images Using a Multi-Scale 3D Convolutional Neural Network. , 2016, , .		4
86	Magnetic resonance imaging phantoms for quality-control of myocardial T1 and ECV mapping: specific formulation, long-term stability and variation with heart rate and temperature. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 62.	3.3	18
87	CMR Guidance for Recanalization of Coronary Chronic Total Occlusion. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 547-556.	5.3	60
88	Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1651-1660.	2.8	92
89	Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	16
90	Comparison of 3T and 1.5T for T2* magnetic resonance of tissue iron. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 40.	3.3	46

#	ARTICLE	IF	CITATIONS
91	P5â€...Aortic dilatation in repaired tetralogy of fallot: Features, determinants and progression. Heart, 2016, 102, A2.2-A3.	2.9	0
92	YI-3â€...Early cardiac remodelling after pulmonary valve replacement in patients with repaired tetralogy of fallot. Heart, 2016, 102, A26-A26.	2.9	1
93	158â€...NT-pro BNP and Survival in Aortic Stenosis. Heart, 2016, 102, A113.2-A114.	2.9	0
94	134â€...Non-invasive Interrogation of Myocardial Disarray in Hypertrophic Cardiomyopathy. Heart, 2016, 102, A96.1-A96.	2.9	0
95	Characterization of left and right atrial function in healthy volunteers by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 64.	3.3	48
96	Myocardial T1 and ECV mapping: how we optimise technical aspects of acquisition. Journal of Cardiovascular Magnetic Resonance, 2016, 18, T9.	3.3	0
97	In-vivo cardiac DTI: An initial comparison of M012 compensated spin-echo and STEAM. Journal of Cardiovascular Magnetic Resonance, 2016, 18, W19.	3.3	3
98	Validation of T2* in-line analysis for tissue iron quantification at 1.5Â. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 23.	3.3	11
99	Value of Formalin Fixation for the Prolonged Preservation of Rodent Myocardial Microanatomical Organization: Evidence by MR Diffusion Tensor Imaging. Anatomical Record, 2016, 299, 878-887.	1.4	15
100	Left atrial dilation in patients with heart failure and preserved ejection fraction: Insights from cardiovascular magnetic resonance. International Journal of Cardiology, 2016, 210, 158-160.	1.7	11
101	Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers. European Heart Journal Cardiovascular Imaging, 2016, 17, 1178-1185.	1.2	19
102	Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 36.	3.3	14
103	Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. PLoS ONE, 2016, 11, e0165262.	2.5	24
104	High prevalence of raised lipoprotein(a) in patients with refractory angina. Global Cardiology Science & Practice, 2015, 2015, 28.	0.4	5
105	Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation. BioMedical Engineering OnLine, 2015, 14, 88.	2.7	11
106	Optimal diffusion weighting for in vivo cardiac diffusion tensor imaging. Magnetic Resonance in Medicine, 2015, 74, 420-430.	3.0	45
107	Systemic Right Ventricular Fibrosis Detected by Cardiovascular Magnetic Resonance Is Associated With Clinical Outcome, Mainly New-Onset Atrial Arrhythmia, in Patients After Atrial Redirection Surgery for Transposition of the Great Arteries. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	74
108	T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 102.	3.3	40



#	ARTICLE	IF	CITATIONS
109	Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology, 2015, 90, 91-96.	4.1	43
110	Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253.	2.2	61
111	The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial. Atherosclerosis Supplements, 2015, 18, 103-108.	1.2	8
112	Neurohormonal activation and its relation to outcomes late after repair of tetralogy of Fallot. Heart, 2015, 101, 447-454.	2.9	34
113	Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a). Journal of Cardiovascular Magnetic Resonance, 2015, 17, P137.	3.3	0
114	The utility of free-breathing, motion-corrected late gadolinium enhancement for right ventricular fibrosis imaging in congenital heart disease. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P221.	3.3	0
115	Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine-Extension of Cordelia Study. Blood, 2015, 126, 2155-2155.	1.4	1
116	Heterogeneity of Fractional Anisotropy and Mean Diffusivity Measurements by In Vivo Diffusion Tensor Imaging in Normal Human Hearts. PLoS ONE, 2015, 10, e0132360.	2.5	26
117	In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 87.	3.3	137
118	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 2014, 100, 1851-1858.	2.9	144
119	Clinical Outcomes of Surgical Pulmonary Valve Replacement After Repair of Tetralogy of Fallot and Potential Prognostic Value of Preoperative Cardiopulmonary Exercise Testing. Circulation, 2014, 129, 18-27.	1.6	151
120	Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients. Annals of Hematology, 2014, 93, 375-379.	1.8	17
121	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in $\beta^2$ -thalassemia major (CORDELIA). Blood, 2014, 123, 1447-1454.	1.4	97
122	Long term effects of cocaine on the heart assessed by cardiovascular magnetic resonance at 3T. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 26.	3.3	60
123	Intercentre reproducibility of cardiac apparent diffusion coefficient and fractional anisotropy in healthy volunteers. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 31.	3.3	33
124	Cardiovascular Magnetic Resonance Determinants of Left Ventricular Noncompaction. American Journal of Cardiology, 2014, 114, 456-462.	1.6	11
125	Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 35.	3.3	1,037
126	Review of Journal of Cardiovascular Magnetic Resonance 2012. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 76.	3.3	5



#	ARTICLE	IF	CITATIONS
127	Right atrial area and right ventricular outflow tract akinetic length predict sustained tachyarrhythmia in repaired tetralogy of Fallot. International Journal of Cardiology, 2013, 168, 3280-3286.	1.7	59
128	Cardiovascular Function and Treatment in $\beta^0$ -Thalassemia Major. Circulation, 2013, 128, 281-308.	1.6	301
129	Automated truncation method for myocardial T2* measurement in thalassemia. Journal of Magnetic Resonance Imaging, 2013, 37, 479-483.	3.4	23
130	In vivo diffusion tensor MRI of the human heart: Reproducibility of breath-hold and navigator-based approaches. Magnetic Resonance in Medicine, 2013, 70, 454-465.	3.0	145
131	The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy. Circulation, 2013, 128, 1623-1633.	1.6	265
132	International survey of T2* cardiovascular magnetic resonance in $\alpha$ -thalassemia major. Haematologica, 2013, 98, 1368-1374.	3.5	62
133	Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. Blood, 2013, 122, 1016-1016.	1.4	3
134	Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With $\beta^0$ -Thalassemia Major: 2-Year Data From The Cordelia Extension. Blood, 2013, 122, 1018-1018.	1.4	4
135	Response to Letter Regarding Article, "Role of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiology". Circulation, 2012, 125, .	1.6	0
136	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with $\alpha$ -thalassemia major. Haematologica, 2012, 97, 842-848.	3.5	122
137	Review of Journal of Cardiovascular Magnetic Resonance 2011. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 75.	3.3	3
138	Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 86.	3.3	78
139	A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with $\beta^0$ -Thalassemia Major and Iron Overload (CORDELIA).. Blood, 2012, 120, 2124-2124.	1.4	4
140	Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. European Heart Journal, 2011, 32, 793-798.	2.2	46
141	Value of black blood T2* cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 21.	3.3	41
142	Review of journal of cardiovascular magnetic resonance 2010. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 48.	3.3	2
143	Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 8.	3.3	28
144	On T2* Magnetic Resonance and Cardiac Iron. Circulation, 2011, 123, 1519-1528.	1.6	381

#	ARTICLE	IF	CITATIONS
145	Continued improvement in myocardial T2* over two years of deferasirox therapy in $\hat{\alpha}$ -thalassemia major patients with cardiac iron overload. Haematologica, 2011, 96, 48-54.	3.5	70
146	Role of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiology. Circulation, 2011, 124, 1351-1360.	1.6	113
147	Efficacy of deferasirox in reducing and preventing cardiac iron overload in $\hat{\alpha}$ -thalassemia. Blood, 2010, 115, 2364-2371.	1.4	168
148	International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. Journal of Magnetic Resonance Imaging, 2010, 32, 315-319.	3.4	139
149	Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 24.	3.3	15
150	Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 65.	3.3	209
151	Late gadolinium enhancement in cardiac sarcoidosis predicts ICD implantation and appropriate discharge. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
152	The predictive value of normal CMR scans in patients with suspected ARVC - an outcomes study. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
153	Recanalization of coronary chronic total occlusion guided by cardiovascular magnetic resonance imaging and its relation with health outcome measures. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
154	Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	2
155	Prognostic CMR predictors of adverse outcomes in patients with suspected ARVC. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
156	Cardiovascular Magnetic Resonance. Circulation, 2010, 121, 692-705.	1.6	244
157	Combined imaging, computational and histological analysis of a ruptured carotid plaque: A patient-specific analysis. Artery Research, 2010, 4, 59.	0.6	7
158	Relation of myocardial T2* to right ventricular function in thalassaemia major. European Heart Journal, 2010, 31, 1648-1654.	2.2	35
159	A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality. Blood, 2010, 116, 1011-1011.	1.4	12
160	Continued Improvement and Normalization of Myocardial T2* In Patients with $\hat{\alpha}$ -thalassemia Major Treated with Deferasirox (Exjade <sup>®</sup> ) for up to 3 Years. Blood, 2010, 116, 4276-4276.	1.4	8
161	On using $T_2^*$ to assess extrinsic magnetic field inhomogeneity effects on $T_2^*$ measurements in myocardial siderosis in thalassemia. Magnetic Resonance in Medicine, 2009, 61, 501-506.	3.0	20
162	Electrocardiographic (ECG) criteria for determining left ventricular mass in young healthy men; data from the LARGE Heart study. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 2.	3.3	31

#	ARTICLE	IF	CITATIONS
163	Cardiovascular Magnetic Resonance in the Evaluation of Hypertrophic and Infiltrative Cardiomyopathies. Heart Failure Clinics, 2009, 5, 369-387.	2.1	14
164	Carotid plaque rupture. Lancet, The, 2009, 374, 1703.	13.7	5
165	T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Haematologica, 2009, 94, 140-141.	3.5	22
166	Calibration of Improved T2* Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload.. Blood, 2009, 114, 2004-2004.	1.4	10
167	Efficacy and Safety of Deferasirox (Exjade®) in $\hat{\text{T}}^2$ -Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	1.4	4
168	Plaque Rupture in the Carotid Artery: A Combined Imaging, Computational and Histological Analysis. , 2009, , .		0
169	Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with $\hat{\text{T}}^2$ -Thalassemia.. Blood, 2009, 114, 5106-5106.	1.4	1
170	Impact of Myocardial Iron Loading On Right Ventricular Function.. Blood, 2009, 114, 2012-2012.	1.4	0
171	Journal of Cardiovascular Magnetic Resonance: Open access in 2008. Journal of Cardiovascular Magnetic Resonance, 2008, 10, 1.	3.3	10
172	Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 2008, 10, 12.	3.3	195
173	Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2008, 10, 42.	3.3	469
174	Myocardial $\langle \text{T} \rangle$ measurement in iron-overloaded thalassemia: An ex vivo study to investigate optimal methods of quantification. Magnetic Resonance in Medicine, 2008, 60, 350-356.	3.0	473
175	Myocardial $\langle \text{T} \rangle$ measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. Magnetic Resonance in Medicine, 2008, 60, 1082-1089.	3.0	132
176	Left-Dominant Arrhythmogenic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 52, 2175-2187.	2.8	590
177	Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox. Blood, 2008, 112, 116-116.	1.4	13
178	Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with $\hat{\text{T}}^2$ -Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. Blood, 2008, 112, 3873-3873.	1.4	12
179	Efficacy and Safety of Deferasirox (Exjade®) in Preventing Cardiac Iron Overload in $\hat{\text{T}}^2$ -Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial. Blood, 2008, 112, 3874-3874.	1.4	9
180	New Publishing Arrangements for JCMR. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 729-729.	3.3	1

#	ARTICLE	IF	CITATIONS
181	Role of delayed enhancement MRI in patients with acute coronary syndrome and unobstructed coronary arteries: reply. <i>European Heart Journal</i> , 2007, 28, 2417-2417.	2.2	0
182	Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 1147-1151.	3.4	81
183	Black-blood T2* technique for myocardial iron measurement in thalassemia. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 1205-1209.	3.4	489
184	Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. <i>British Journal of Haematology</i> , 2007, 138, 587-593.	2.5	92
185	Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1977-1985.	2.8	1,026
186	Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. <i>Blood</i> , 2006, 107, 3738-3744.	1.4	424
187	Ventricular Fibrosis Suggested by Cardiovascular Magnetic Resonance in Adults With Repaired Tetralogy of Fallot and Its Relationship to Adverse Markers of Clinical Outcome. <i>Circulation</i> , 2006, 113, 405-413.	1.6	536
188	Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. <i>European Heart Journal</i> , 2006, 27, 2879-2888.	2.2	490
189	Improved Endothelial Function with Combined Chelation Therapy in Thalassemia Major.. <i>Blood</i> , 2006, 108, 1770-1770.	1.4	9
190	Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. <i>Haematologica</i> , 2006, 91, 1388-91.	3.5	113
191	T2* Magnetic Resonance and Myocardial Iron in Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 373-378.	3.8	148
192	Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 22, 229-233.	3.4	73
193	Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassemia. <i>International Journal of Cardiovascular Imaging</i> , 2005, 21, 531-538.	1.5	104
194	Late Gadolinium Enhancement Cardiovascular Magnetic Resonance of the Systemic Right Ventricle in Adults With Previous Atrial Redirection Surgery for Transposition of the Great Arteries. <i>Circulation</i> , 2005, 111, 2091-2098.	1.6	260
195	Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 1292-1297.	5.6	345
196	Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).. <i>Blood</i> , 2005, 106, 3600-3600.	1.4	23
197	A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance.. <i>Blood</i> , 2005, 106, 3655-3655.	1.4	8
198	Inter-Site Validation of a Single Breath Hold T2* MR Technique for Heart and Liver Iron Measurement.. <i>Blood</i> , 2005, 106, 3830-3830.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Calibration of Myocardial T2* Values in Post-Mortem Hearts.. Blood, 2005, 106, 3837-3837.	1.4	3
200	Myocardial T2* in Patients with Cardiac Failure Secondary to Iron Overload.. Blood, 2005, 106, 3838-3838.	1.4	10
201	Myocardial T2* Is Not Affected by the Structural Effects of Myocardial Fibrosis, Ageing or Impaired Left Ventricular Function.. Blood, 2005, 106, 1675-1675.	1.4	1
202	Validation of T2* Technique in Ex-Vivo Myocardial Tissue.. Blood, 2005, 106, 3718-3718.	1.4	2
203	The Effect of Combined Chelation Therapy in the Treatment of Severe Myocardial Iron Loading in Beta Thalassaemia Major.. Blood, 2005, 106, 3836-3836.	1.4	0
204	Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.. Blood, 2005, 106, 2707-2707.	1.4	1
205	Role of Magnetic Resonance Angiography in the Diagnosis of Major Aortopulmonary Collateral Arteries and Partial Anomalous Pulmonary Venous Drainage. Circulation, 2004, 109, 207-214.	1.6	141
206	Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 2004, 127, 348-355.	2.5	340
207	Cardiovascular magnetic resonance and the role of adenosine pharmacologic stress. American Journal of Cardiology, 2004, 94, 26-31.	1.6	28
208	Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report?. European Heart Journal, 2004, 25, 1940-1965.	2.2	649
209	The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 43, 2260-2264.	2.8	628
210	Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. American Heart Journal, 2004, 147, 218-223.	2.7	686
211	Comparison of equilibrium radionuclide ventriculography with cardiovascular magnetic resonance for assessing the systemic right ventricle after Mustard or Senning procedures for complete transposition of the great arteries. American Journal of Cardiology, 2003, 92, 640-643.	1.6	26
212	A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. Journal of Magnetic Resonance Imaging, 2003, 18, 33-39.	3.4	741
213	Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. Journal of Magnetic Resonance Imaging, 2003, 18, 616-620.	3.4	149
214	MR Imaging of Arrhythmogenic Right Ventricular Cardiomyopathy: Morphologic Findings and Interobserver Reliability. Cardiology, 2003, 99, 153-162.	1.4	179
215	Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet, The, 2003, 361, 183-184.	13.7	14
216	Cardiovascular magnetic resonance: twenty-first century solutions in cardiology. Clinical Medicine, 2003, 3, 273-278.	1.9	66

#	ARTICLE	IF	CITATIONS
217	Myocardial Fibrosis in Glycogen Storage Disease Type III. <i>Circulation</i> , 2003, 107, e47.	1.6	42
218	Ventricular Volume and Mass by CMR. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2003, 4, 507-513.	3.3	139
219	Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance. <i>Hypertension</i> , 2002, 39, 750-755.	2.7	256
220	Breath-hold FLASH and FISP Cardiovascular MR Imaging: Left Ventricular Volume Differences and Reproducibility. <i>Radiology</i> , 2002, 223, 789-797.	7.3	270
221	Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2002, 4, 203-210.	3.3	132
222	Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. <i>Circulation</i> , 2002, 105, 539-542.	1.6	5,371
223	Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. <i>Lancet, The</i> , 2002, 360, 516-520.	13.7	394
224	Magnetic resonance imaging in the assessment of patients with heart failure. <i>Journal of Nuclear Cardiology</i> , 2002, 9, S60-S70.	2.1	1
225	Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. <i>American Journal of Cardiology</i> , 2002, 90, 29-34.	1.6	1,259
226	Evaluation of free-breathing three-dimensional magnetic resonance coronary angiography with hybrid ordered phase encoding (HOPE) for the detection of proximal coronary artery stenosis. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 677-684.	3.4	16
227	Echo-planar magnetic resonance myocardial perfusion imaging: Parametric map analysis and comparison with thallium SPECT. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 13, 192-200.	3.4	105
228	The role of cardiovascular magnetic resonance in heart failure. <i>European Journal of Heart Failure</i> , 2000, 2, 241-252.	7.1	47
229	A comparison between segmented k-space FLASH and interleaved spiral MR coronary angiography sequences. <i>Journal of Magnetic Resonance Imaging</i> , 2000, 11, 394-400.	3.4	31
230	Left ventricular quantification in heart failure by cardiovascular MR using prospective respiratory navigator gating: Comparison with breath-hold acquisition. <i>Journal of Magnetic Resonance Imaging</i> , 2000, 11, 411-417.	3.4	35
231	Quantification of Right and Left Ventricular Function by Cardiovascular Magnetic Resonance. <i>Herz</i> , 2000, 25, 392-399.	1.1	73
232	Establishment and Performance of a Magnetic Resonance Cardiac Function Clinic. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2000, 2, 15-22.	3.3	84
233	Contrast-Enhanced Magnetic Resonance Angiogram of Coronary Artery Bypass Graft Aneurysm. <i>Circulation</i> , 2000, 102, 3148-3148.	1.6	3
234	Reduction in Sample Size for Studies of Remodeling in Heart Failure by the Use of Cardiovascular Magnetic Resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2000, 2, 271-278.	3.3	583

#	ARTICLE	IF	CITATIONS
235	Left ventricular function and mass after orthotopic heart transplantation: a comparison of cardiovascular magnetic resonance with echocardiography. Journal of Heart and Lung Transplantation, 2000, 19, 444-452.	0.6	65
236	Magnetic resonance navigator echo diaphragm monitoring in patients with suspected diaphragm paralysis. Journal of Magnetic Resonance Imaging, 1999, 9, 69-74.	3.4	29
237	Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. Journal of Magnetic Resonance Imaging, 1999, 9, 220-227.	3.4	141
238	Automated monitoring of diaphragm end-expiratory position for real-time navigator echo MR coronary angiography. Journal of Magnetic Resonance Imaging, 1999, 9, 395-401.	3.4	31
239	Differences between normal subjects and patients with coronary artery disease for three different MR coronary angiography respiratory suppression techniques. Journal of Magnetic Resonance Imaging, 1999, 9, 786-793.	3.4	66
240	First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection. Journal of Magnetic Resonance Imaging, 1999, 10, 404-410.	3.4	39
241	Nuclear cardiology in clinical practice. British Journal of Hospital Medicine, 1999, 60, 183-186.	0.2	0
242	Hybrid ordered phase encoding (HOPE): An improved approach for respiratory artifact reduction. Journal of Magnetic Resonance Imaging, 1998, 8, 968-980.	3.4	55
243	Comparison of fast spiral, echo planar, and fast low-angle shot MRI for cardiac volumetry at .5T. Journal of Magnetic Resonance Imaging, 1998, 8, 1033-1039.	3.4	20
244	MR as a diagnostic tool in heart disease: What is the future?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 1998, 6, 189-190.	2.0	5
245	A comparison of adenosine and arbutamine for myocardial perfusion imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 394-400.	6.4	7
246	MR navigator-echo monitoring of temporal changes in diaphragm position: Implications for MR coronary angiography. Journal of Magnetic Resonance Imaging, 1997, 7, 629-636.	3.4	189
247	Magnetic resonance imaging during dobutamine stress in coronary artery disease. American Journal of Cardiology, 1992, 70, 34-40.	1.6	216
248	Unusual Cardiomyopathies—Role of Cardiac Magnetic Resonance Imaging. , 0, , 251-260.		0
249	Pediatric Cardiac Magnetic Resonance Reference Values for Biventricular Volumes Derived From Different Contouring Techniques. Journal of Magnetic Resonance Imaging, 0, , .	3.4	4